ClinicalTrials.gg
Not yet recruitingNCT06106061FFX® RCTUpdated Oct 30, 2023

Effectiveness and Safety of the Facet Fixation (FFX®) Implant in the Treatment of Degenerative Lumbar Spinal Stenosis

An interventional study of Decompression + FFX® and Decompression alone in Degenerative Lumbar Spinal Stenosis, sponsored by SC Medica. Not yet recruiting. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-10-30.

Sponsored by SC Medica · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

This is a prospective, multicentric, comparative, randomised-controlled study to evaluate the safety and efficacy of the Facet Fixation implant.

The main objective is to evaluate the effectiveness of spinal decompression associated with FFX® implants compared to spinal decompression alone in treating lumbar spinal stenosis after 2 years of treatment.

02

Conditions studied

  • Degenerative Lumbar Spinal Stenosis

Browse trials for

03

In context

Spinal Stenosis

458 studies on the registry are indexed under Spinal Stenosis; 105 are open to participants now.

This study's planned enrollment of 320 is above the median of 80 across 281 interventional studies indexed under Spinal Stenosis.

Browse Spinal Stenosis studies →

Lead sponsor

SC Medica is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50 years.
  • Radiographic confirmation of clinical symptoms of at least moderate degenerative spinal stenosis, of 1 to 3 adjacent segments in the L1-S1 region with the need for surgical decompression.
  • Radiographic confirmation of no translational instability in main segment as well as in adjacent segments (dynamic translational instability ≤3 mm);
  • Visual analogue scale (VAS) back pain score ≥ 50 mm (on a 100-mm scale).
  • Minimum of 3 months of conservative therapy without improvement of symptoms.
  • Mental \& physical ability of the subject to follow the protocol (i.e., compliance with time schedule \& treatment plan, able to fill in questionnaire \& to undergo further study procedures).
  • Personally signed and dated document prior to any study-related procedures indicating that the subject has been informed of all pertinent aspects of the clinical investigation.

Exclusion criteria

Exclusion Criteria:

  • Prior lumbar spine surgery.
  • Radiographically confirmed damage of a vertebral body (e.g., osteoporotic compression fracture or because of tumours), at any lumbar level.
  • Isthmic or degenerative spondylolisthesis (anterolisthesis; retrolisthesis ≥ grade II) or spondylolysis (pars fracture).
  • Degenerative lumbar scoliosis (Cobb angle > 25°).
  • Adipositas (obesity); defined as a (BMI) >40.
  • Pregnancy, or wish to get pregnant during the course of the study, or breastfeeding.
  • Known allergy or sensitivity to titanium, titanium alloys, or MRI contrast agents.
  • Active or chronic infection-systemic or local.
  • History of significant peripheral neuropathy.
  • Significant peripheral vascular disease (e.g., with diminished dorsalis pedis or posterior tibial pulses).
  • Paget disease, osteomalacia or other metabolic bone disorders.
  • Cauda equina syndrome.
  • Known or documented history of transmissible disease, including AIDS, and active hepatitis.
  • More than 3 vertebral levels requiring surgery.
  • Disc herniation at any lumbar level requiring surgical intervention.
  • Known osteoporosis (bone mineral density, BMD \< 120 mg/cm3).
  • Chronically taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., ), not including a Medrol (methylprednisolone) dose pack.
  • Fixed and complete motor, sensory, or reflex deficit.
  • Rheumatoid arthritis or other diseases.
  • Active : a subject with a history of any invasive malignancy (except non-melanoma skin cancer) unless he/she has been treated with curative intent and there has been no clinical signs or symptoms of the malignancy for at least 5 years. Subjects with a primary bony tumour are excluded as well.
  • Subject with a history of substance abuse (e.g., recreational drugs, narcotics, or alcohol).
  • Bone destruction, demineralisation or any affection potentially affecting fixation of an implant.
  • Spondylodiscitis or spine tumour.
  • Currently seeking or receiving workman's compensation.
  • In active spinal litigation.
  • Subjects who participate(d) in another clinical trial (within the last 4 weeks) that might influence the safety \& effectiveness assessment of this trial.
  • Subjects who are lawfully kept in an institution.
  • Subject who, in the opinion of the investigator, will be inappropriate for inclusion in this clinical trial or who will not comply with requirements of the study.
  • Subject under supervision or legal guardianship, or judicial protection.
  • Subject deprived of liberty by judicial or administrative decision.
  • Subject not covered by a social security scheme.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Group one: Decompression + FFX®

    Device: Decompression + FFX®

  • Active comparator
    Group two: Decompression alone

    Procedure: Decompression alone

Interventions

  • DeviceDecompression + FFX®

    Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression associated with the use of FFX® implant

  • ProcedureDecompression alone

    Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression alone

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with composite clinical success (CCS)

    The CCS will be considered as met if ALL of the following criteria are satisfied for a subject: * Back pain score (VAS) decrease by more than 20 mm (on 100-mm scale) * No secondary surgical intervention at the index level (excluding wound problems) * No non-surgical lumbar treatment of interest at any lumbar level

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Nov 2026, 36 months later.

Of 123 interventional studies with no phase under Spinal Stenosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Oct 30, 2023
StartEst.
Nov 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Oct 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06106061
Lead sponsor
SC Medica
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Nov 2023 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 30, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion